Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement

Inflammatory Bowel Diseases

Volumn 19, Issue 9, 2013, Pages 1983-1989

  Jurisic, Giorgia ^a,c   Sundberg, John P ^b   Detmar, Michael ^a  

^a ETH ZURICH   (Switzerland)

^b JACKSON LABORATORY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Colitis; Lymphangiogenesis; VEGFR 3

Indexed keywords

INTERLEUKIN 10; RECEPTOR ANTIBODY; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CELL INFILTRATION; CHRONIC INFLAMMATION; COLITIS; COLON; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EDEMA; EXPERIMENTAL MODEL; FEMALE; LEUKOCYTE; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBMUCOSA; VASCULARIZATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; MICE, KNOCKOUT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84884609221     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829292f7     Document Type: Article

References (34)

1. Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17:1371-1380.
2. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-198.
3. Huggenberger R, Ullmann S, Proulx ST, et al. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med. 2010;207:2255-2269.
4. Kerjaschki D, Regele HM, Moosberger I, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004;15:603-612.
5. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92:3566-3570.
6. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454: 656-660.
7. Makinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001;20:4762-4773.
8. Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2000;25:153-159.
9. Ghalamkarpour A, Morlot S, Raas-Rothschild A, et al. Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. Clin Genet. 2006;70:330-335.
10. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A. 2001;98: 12677-12682.
11. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199-205.
12. Kajiya K, Detmar M. An important role of lymphatic vessels in the control of UVB-induced edema formation and inflammation. J Invest Dermatol. 2006;126:919-921.
13. Baluk P, Tammela T, Ator E, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 2005; 115:247-257.
14. Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol. 2006;4:217-228.
15. Kataru RP, Jung K, Jang C, et al. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood. 2009;113:5650-5659.
16. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673.
17. Bristol IJ, Farmer MA, Cong Y, et al. Heritable susceptibility for colitis in mice induced by IL-10 deficiency. Inflamm Bowel Dis. 2000;6:290-302.
18. Deban L, Correale C, Vetrano S, et al. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol. 2008;172:1457-1466.
19. Jurisic G, Sundberg JP, Bleich A, et al. Quantitative lymphatic vessel trait analysis suggests Vcam1 as candidate modifier gene of inflammatory bowel disease. Genes Immun. 2010;11:219-231.
20. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 2005;97:14-21.
21. Bleich A, Mahler M, Most C, et al. Refined histopathologic scoring system improves power to detect colitis QTL in mice. Mamm Genome. 2004; 15:865-871.
22. de Buhr MF, Hedrich HJ, Westendorf AM, et al. Analysis of Cd14 as a genetic modifier of experimental inflammatory bowel disease (IBD) in mice. Inflamm Bowel Dis. 2009;15:1824-1836.
23. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol. 2001;159: 893-903.
24. Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161:947-956.
25. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
26. Halin C, Detmar M. Chapter 1. Inflammation, angiogenesis, and lymphangiogenesis. Methods Enzymol. 2008;445:1-25.
27. Ganta VC, Cromer W, Mills GL, et al. Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis. 2010;16:1029-1039.
28. Alexander JS, Chaitanya GV, Grisham MB, et al. Emerging roles of lymphatics in inflammatory bowel disease. Ann N Y Acad Sci. 2010; 1207(suppl 1):E75-E85.
29. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med. 2004;10: 813-815.
30. Gordon EJ, Rao S, Pollard JW, et al. Macrophages define dermal lymphatic vessel calibre during development by regulating lymphatic endothelial cell proliferation. Development. 2010;137:3899-3910.
31. Laakkonen P, Waltari M, Holopainen T, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007;67:593-599.
32. Guo R, Zhou Q, Proulx ST, et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum. 2009;60:2666-2676.
33. Heatley RV, Bolton PM, Hughes LE, et al. Mesenteric lymphatic obstruction in Crohn's disease. Digestion. 1980;20:307-313.
34. Alexander JS, Ganta VC, Jordan PA, et al. Gastrointestinal lymphatics in health and disease. Pathophysiology. 2010;17:315-335.